Oral SMAD7 antisense drug for crohn's disease

New England Journal of Medicine

Volumn 372, Issue 12, 2015, Pages 1166-1167

  Vermeire, Severine ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CALGRANULIN; INFLIXIMAB; MESSENGER RNA; MONGERSEN; PLACEBO; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VEDOLIZUMAB; GED0301; IMMUNOSUPPRESSIVE AGENT; OLIGONUCLEOTIDE; SMAD7 PROTEIN, HUMAN;

ANTISENSE THERAPY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PROTEIN BINDING; EDITORIAL; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REMISSION; SIGNAL TRANSDUCTION; ULCER HEALING; ANTAGONISTS AND INHIBITORS; FEMALE; MALE;

CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; OLIGONUCLEOTIDES; SMAD7 PROTEIN;

EID: 84925068548     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1415053     Document Type: Editorial

References (8)

1. Crohn BB, Ginzburg L, Oppenheimer GD. Landmark article Oct 15, 1932. Regional ileitis: a pathological and clinical entity. By Burrill B. Crohn, Leon Ginzburg, and Gordon D. Oppenheimer. JAMA 1984;251:73-9.
2. Boirivant M, Pallone F, Di Giacinto C, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGFbeta1-mediated suppression of colitis. Gastroenterology 2006; 131:1786-98.
3. Monteleone G, Neurath MF, Ardizzone S, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med 2015;372:1104-13.
4. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
5. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130: 323-33.
6. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21.
7. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006; 12:99-106.
8. Medina C, Santos-Martinez MJ, Santana A, et al. Transforming growth factor-beta type 1 receptor (ALK5) and Smad proteins mediate TIMP-1 and collagen synthesis in experimental intestinal fibrosis. J Pathol 2011;224:461-72.